Update on adjuvant therapy in completely resected NSCLC patients

Area of Science:

• Oncology
• Pulmonology
• Pharmacology

Background:

• Postoperative adjuvant chemotherapy improves survival in resected non-small cell lung cancer (NSCLC) by reducing recurrence risk.
• Platinum-based chemotherapy has been the standard adjuvant treatment following complete resection.
• Recent advancements include targeted therapies and immunotherapies, altering the treatment landscape.

Purpose of the Study:

• To review key considerations in selecting adjuvant treatment for completely resected NSCLC.
• To provide updates on novel treatment modalities in the postoperative setting.

Main Methods:

• Review of existing literature and clinical trial data.
• Discussion of landmark studies, including the ADAURA trial.
• Analysis of emerging treatment strategies.

Main Results:

• The ADAURA study demonstrated superior disease-free survival with adjuvant osimertinib compared to placebo in completely resected NSCLC (IB-IIIA).
• Third-generation TKIs and immunotherapy represent significant advancements.

Conclusions:

• Adjuvant osimertinib is a key advancement for specific NSCLC patient populations.
• The choice of adjuvant treatment requires careful consideration of evolving therapeutic options.